Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

Link to full article MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the first patient has been dosed in the company’s Phase 1b/2a clinical trial (‘diSArm’) of AP-SA02, which is […]

Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

Link to full article Feb. 22, 2022 Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared Armata’s Investigational New Drug (IND) application to initiate a clinical trial of […]

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development

Link to full article Feb. 9, 2022 Armata intends to use the net proceeds from this transaction to advance its clinical pipeline and strengthen its bacteriophage platform. The clinical pipeline is led by AP-PA02, currently under evaluation in the ‘SWARM-P.a.‘ trial as a novel therapeutic to treat chronic Pseudomonas aeruginosa infections in people with cystic fibrosis. A […]

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Link to full article Enhanced AP-PA02 enters SWARM-P.a. study AP-PA02 identified as lead cocktail for non-cystic fibrosis bronchiectasis Phase 2 trial Distinct phage cocktail (AP-PA03) for pneumonia advances to manufacturing Jan. 5, 2022 The improvements in AP-PA02 reflect Armata’s core strategy of utilizing clinical isolate surveillance data to drive enhancement of product composition. Prior to […]

Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs

Link to full article Nov. 18, 2021 Announces FDA clearance of IND to initiate Phase 1b/2a clinical trial of AP-SA02 in Staphylococcus aureus bacteremia (“diSArm” Study) Achieves significant milestone under previously announced therapeutic development award from the Cystic Fibrosis Foundation for continued advancement of Phase 1b/2a SWARM-P.a. clinical trial of AP-PA02 in Pseudomonas aeruginosa infections […]

Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals

Link to full article Funds to be used to further advance development of lead candidate AP-PA02, which is being evaluated in a Phase 1b/2a clinical trial in Pseudomonas aeruginosa respiratory infections in CF patients Innoviva, a significant Armata shareholder, also elected to participate Oct. 28, 2021 In accordance with the terms of the investment agreement, […]

Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update

Link to Full Article Continues to advance AP-PA02 through Phase 1b/2a clinical trial as a potential treatment for cystic fibrosis patients with chronic Pseudomonas aeruginosa Announced that Todd R. Patrick, CEO, has retired from the Company. Brian Varnum, PhD, former President and Chief Development Officer, has been appointed the Company’s new CEO MARINA DEL REY, […]

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update

Link to Full Article Company earns $750,000 milestone payment related to SWARM-P.a. Study MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided […]

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update

Link to Full Article MARINA DEL REY, Calif., March 18, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the fourth quarter and full year 2020 and provided a corporate and clinical update. Fourth Quarter […]

Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’s Bacteriophage Development Programs

Link to Full Article MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva […]